For example, shortness of breath in A1AD emphysema often begins in early middle age when many individuals are facing the developmental tasks of generativity (aiding the development of the younger generations) versus stagnation (investing only in oneself) (Erikson, 1963), and families are launching their children or have just finished this process.
In genetic illness with late onset of symptoms such A1AD emphysema, the development of many generations may be affected by the diagnosis of an illness which they all may share.
AGTC's treatment for A1AD utilizes its Adeno-Associated Virus technology to deliver the normal human gene to patients so their body can produce the missing protein.
Extensive pre-clinical work has been completed on the Company's treatment for A1AD and AGTC is currently raising a Series B venture investment of $12 million in order to fund Human Clinical Trials and scale-up its production process to support market launch.
AGTC is currently raising a Series B venture investment of $12 million in order to fund Phase II Human Clinical Trials for its A1AD
product and to scale-up its production process to support market launch.
AAV vectors treating A1AD and Pompe's are two of several novel gene therapy treatments, for both human and veterinary uses, that AGTC is developing.
The six million dollar investment will be used by AGTC to complete pre-clinical toxicology studies and Phase I Human Clinical Trials for A1AD and to complete the development of its proprietary, large scale AAV production method.